PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
8.78%
Revenue growth above 1.5x MRVL's 4.91%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
11.98%
Gross profit growth 1.25-1.5x MRVL's 8.94%. Bruce Berkowitz would see if strategic sourcing or brand premium explains outperformance.
24.51%
EBIT growth 1.25-1.5x MRVL's 21.01%. Bruce Berkowitz would verify if strategic initiatives are driving this edge.
24.51%
Operating income growth 1.25-1.5x MRVL's 21.01%. Bruce Berkowitz would see if strategic measures (e.g., cost cutting, product mix) are succeeding.
21.84%
Net income growth above 1.5x MRVL's 1.60%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
14.00%
EPS growth above 1.5x MRVL's 3.13%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
18.75%
Diluted EPS growth of 18.75% while MRVL is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
1.23%
Share count expansion well above MRVL's 0.05%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.00%
Slight or no buyback while MRVL is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
-51.00%
Negative OCF growth while MRVL is at 38.12%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-62.58%
Negative FCF growth while MRVL is at 29.18%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
517.81%
10Y revenue/share CAGR at 75-90% of MRVL's 680.69%. Bill Ackman would press for new markets or product lines to narrow the gap.
65.46%
5Y revenue/share CAGR at 50-75% of MRVL's 114.05%. Martin Whitman would worry about a lagging mid-term growth trajectory.
14.54%
3Y revenue/share CAGR at 50-75% of MRVL's 27.26%. Martin Whitman would question if the firm lags behind competitor innovations.
954.88%
10Y OCF/share CAGR under 50% of MRVL's 5190.81%. Michael Burry would worry about a persistent underperformance in cash creation.
-33.39%
Negative 5Y OCF/share CAGR while MRVL is at 258.26%. Joel Greenblatt would question the firm’s operational model or cost structure.
-69.21%
Negative 3Y OCF/share CAGR while MRVL stands at 2986.27%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
624.87%
Net income/share CAGR above 1.5x MRVL's 136.31% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
160.46%
5Y net income/share CAGR at 50-75% of MRVL's 222.25%. Martin Whitman might see a shortfall in operational efficiency or brand power.
-17.86%
Negative 3Y CAGR while MRVL is 236.87%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
1627.00%
Positive growth while MRVL is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
115.78%
5Y equity/share CAGR above 1.5x MRVL's 52.93%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
36.06%
3Y equity/share CAGR 1.25-1.5x MRVL's 28.61%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.75%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
19.10%
Inventory growth well above MRVL's 0.97%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
3.53%
Asset growth at 50-75% of MRVL's 5.79%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
8.62%
1.25-1.5x MRVL's 7.53%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
-1.25%
We’re deleveraging while MRVL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
9.25%
R&D growth drastically higher vs. MRVL's 0.07%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
2.56%
SG&A declining or stable vs. MRVL's 14.49%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.